Cenicriviroc

Cenicriviroc Structure
CAS No.
497223-25-3
Chemical Name:
Cenicriviroc
Synonyms
TAK652;TBR652;TBR-652;CS-2572;TBR 652;Cenicriviroc;Cenicriviroc(TAK652);TAK-652 or Cenicriviroc;Cenicriviroc mesylate (TAK-652);TAK-652; TBR-652; TAK652; TBR652; TAK 652; TBR 652
CBNumber:
CB72627679
Molecular Formula:
C41H52N4O4S
Molecular Weight:
696.94
MOL File:
497223-25-3.mol
Modify Date:
2024/7/2 8:55:16

Cenicriviroc Properties

Boiling point 913.5±65.0 °C(Predicted)
Density 1.17±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMF: 20 mg/ml; DMSO: 20 mg/ml; DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml; Ethanol: 5 mg/ml
form A crystalline solid
pka 12.96±0.70(Predicted)
color Light yellow to yellow

SAFETY

Risk and Safety Statements

Cenicriviroc Chemical Properties,Uses,Production

Description

Cenicriviroc is a dual antagonist of chemokine receptor types 2 and 5 (CCR2/CCR5). The receptors are found on Kupffer cells and hepatic stellate cells, and preclinical studies suggest its anti-inflammatory and anti-fibrotic activity. In the phase 2b CENTAUR study, cenicriviroc treatment for 1 year failed to achieve the primary outcome of a decrease in NAFLD activity score by ≥2 points with no worsening of fibrosis. Nonetheless, one of the key secondary outcomes, improvement in liver fibrosis without worsening of NASH, was achieved in 20% in the treatment group, compared with 10% in the placebo group. Besides, cenicriviroc reduced the serum levels interleukin- 6, C-reactive protein and fibrinogen, suggesting its action on inflammation that may not be reflected by crude histological assessment. A phase 3 study is planned.

Uses

Cenicriviroc is an experimental drug candidate for the treatment of HIV infection. It is an inhibitor of CCR2 and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell.

Clinical Use

Cenicriviroc is a small molecule inhibitor of both CCR2 and CCR5, and has demonstrated safety in early trials of human patients afflicted with HIV-1, as well as a phase IIb trial (ClinicalTrials.gov NCT01338883). Cenicriviroc has also demonstrated therapeutic potential in animal models of liver fibrosis as well as renal fibrosis. A phase II trial of cenicriviroc in patients with NASH and liver fibrosis is planned to complete in late 2017 and (ClinicalTrials.gov NCT02217475). This trial, also called “CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects With Liver Fibrosis,” is a double-blind, placebo-controlled, randomized multinational study with the primary endpoint being histologic improvement of NASH activity score without worsening of fibrosis in patients with NASH and liver fibrosis. Results of this study are pending. An open label rollover extension study of participants in CENTAUR began in early 2017 and is ongoing (ClinicalTrials. gov NCT03059446).
There is evidence that CCRs are important in fibrosis in the liver, lung and kidney. At least one molecule that inhibits CCRs has demonstrable safety in human subjects. As such, blockade of CCRs with molecules such as Cenicriviroc represent another potential therapeutic avenue for the treatment of fibrotic inflammatory bowel disease.

Cenicriviroc Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 84)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
ATK CHEMICAL COMPANY LIMITED +undefined-21-51877795 China 32760 60 Inquiry
BOC Sciences +1-631-485-4226 United States 19553 58 Inquiry
Career Henan Chemica Co +86-0371-86658258 +8613203830695 China 30253 58 Inquiry
Alfa Chemistry +1-5166625404 United States 21317 58 Inquiry
Hangzhou Proserre Chemical Co.,Ltd. +86-571-86088112 China 1077 58 Inquiry
InvivoChem +1-708-310-1919 +1-13798911105 United States 6393 58 Inquiry
Zibo Hangyu Biotechnology Development Co., Ltd +86-0533-2185556 +8617865335152 China 11027 58 Inquiry
LEAPCHEM CO., LTD. +86-852-30606658 China 43348 58 Inquiry
Shanxi Tihondan Pharmaceutical Technology Co., Ltd +8618235132063 China 3725 58 Inquiry

497223-25-3(Cenicriviroc)Related Search:

Cenicriviroc TAK652 Cenicriviroc mesylate (TAK-652) Cenicriviroc(TAK652) TAK-652; TAK652; TAK 652; TBR-652; TBR 652; TBR652; CENICRIVIROC. CS-2572 TAK-652; TBR-652; TAK652; TBR652; TAK 652; TBR 652 TBR 652 TBR652 TBR-652 1-Benzazocine-5-carboxamide, 8-[4-(2-butoxyethoxy)phenyl]-1,2,3,4-tetrahydro-1-(2-methylpropyl)-N-[4-[(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]- (S,E)-8-(4-(2-butoxyethoxy)phenyl)-1-isobutyl-N-(4-(((1-propyl-1H-imidazol-5-yl)methyl)sulfinyl)phenyl)-1,2,3,4-tetrahydrobenzo[b]azocine-5-carboxamide TAK-652 or Cenicriviroc (S)-8-(4-(2-Butoxyethoxy)phenyl)-1-isobutyl-N-(4-(((1-propyl-1H-imidazol-5-yl)methyl)sulfinyl)phenyl)-1,2,3,4-tetrahydrobenzo[b]azocine-5-carboxamide 497223-25-3 C41H52N4O4S